Statement: the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET, MRI and dosimetry 
Primary_evidence: INTERVENTION 1:    IPAS   Once the patient recorded in the trial, and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk, the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate, delivering a total dose of 16 Gy in one fraction IPAS
Secondary_evidence: INTERVENTION 1:    Zr89-trastuzumab PET/CT   Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm